

openMetaAnalysis: PICO Table

Trial	Patients	Intervention	Comparison	Outcome
Corren (PATHWAY) N Engl J Med. 2017 PMID: 28877011 NCT02054130	275 subjects with severe asthma • Blood eosinophil count 380 cells/ μ l • Prebronchodilator FEV1 1.82 liters/minute	Tezepelumab 210 mg subcutaneously every 4 weeks.	Placebo	Primary: • Relative reduction of annualized rate of asthma exacerbations (ARAE) that required emergency care or hospitalization Secondary: • Others
Menzies-Gow (NAVIGATOR). N Engl J Med. 2021 PMID: 33979488 NCT03347279	1061 subjects with severe asthma • Blood eosinophil count 327 cells/ μ l • Prebronchodilator FEV1 62% of predicted	Tezepelumab 210 mg subcutaneously every 4 weeks.	Placebo	Primary: • Relative reduction of annualized rate of asthma exacerbations (ARAE) that required emergency care or hospitalization Secondary: • Others
Trial	Patients	Intervention	Comparison	Outcome